NeoGenomics, Inc. (NASDAQ:NEO) Shares Bought by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lifted its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 3.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,505 shares of the medical research company’s stock after acquiring an additional 1,030 shares during the period. Oppenheimer Asset Management Inc.’s holdings in NeoGenomics were worth $451,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Bellevue Group AG bought a new stake in NeoGenomics during the first quarter valued at $14,872,000. First Light Asset Management LLC boosted its holdings in shares of NeoGenomics by 29.6% in the 4th quarter. First Light Asset Management LLC now owns 3,926,756 shares of the medical research company’s stock valued at $63,535,000 after buying an additional 897,843 shares during the period. Norges Bank bought a new stake in shares of NeoGenomics during the 4th quarter valued at about $14,512,000. Kopp LeRoy C acquired a new stake in NeoGenomics during the first quarter worth about $14,062,000. Finally, Jennison Associates LLC lifted its holdings in NeoGenomics by 77.8% in the first quarter. Jennison Associates LLC now owns 1,051,627 shares of the medical research company’s stock worth $16,532,000 after acquiring an additional 460,071 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on NEO shares. Stephens reaffirmed an “overweight” rating and set a $19.00 target price on shares of NeoGenomics in a report on Tuesday, July 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a research report on Tuesday, July 30th. Finally, Benchmark reiterated a “buy” rating and issued a $18.00 target price on shares of NeoGenomics in a research note on Tuesday, July 30th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.89.

NeoGenomics Price Performance

Shares of NASDAQ NEO opened at $16.28 on Friday. The stock has a market cap of $2.08 billion, a P/E ratio of -24.67 and a beta of 1.19. The firm’s 50-day simple moving average is $16.05 and its 200 day simple moving average is $14.95. NeoGenomics, Inc. has a fifty-two week low of $11.03 and a fifty-two week high of $21.22. The company has a quick ratio of 1.93, a current ratio of 2.01 and a debt-to-equity ratio of 0.37.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Monday, July 29th. The medical research company reported $0.03 EPS for the quarter. The company had revenue of $164.50 million for the quarter, compared to the consensus estimate of $161.82 million. NeoGenomics had a negative net margin of 12.50% and a negative return on equity of 2.72%. NeoGenomics’s revenue was up 12.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.09) EPS. Equities analysts expect that NeoGenomics, Inc. will post -0.22 EPS for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.